Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease - Eli Lilly and Co (NYSE:LLY), Roche Holding (OTC:RHHBY)

Roche RHHBY announces collaboration with Eli Lilly and Company LLY to support the development of its Elecsys Amyloid Plasma Panel (EAPP).
The EAPP is a blood test that aims to facilitate the earlier diagnosis of Alzheimer’s disease.
If approved, the EAPP test would be an additional tool to identify low likelihood of amyloid pathology in symptomatic patients and determine whether they should proceed to further evaluation and testing that may confirm a diagnosis.
Also Read: New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients
Roche's Elecsys beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys Phospho-Tau (181P) CSF (pTau181) assays, which identify Alzheimer's pathology in its early symptomatic stage, gained FDA 510(k) clearance in December 2022.
Price Action: RHHBY closed higher by 1.37% at $35.62 on Tuesday.